STAA

STAAR SURGICAL CO

Healthcare | Small Cap

$0.10

EPS Forecast

$82.82

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Clear Vision, Clearer Margins: STAAR Surgical's Q1 2026 Momentum (STAA)

ticker: STAA • EPS reported: $0.10 per diluted share • revenue forecast implications in view • earnings surprise considerations remain contingent on EPS consensus and market expectations.

Executive snapshot

STAAR Surgical Corporation, listed under the ticker STAA, reported an impressive first quarter of 2026, driven by top-line momentum and a strong gross margin. The company posted net sales of $93.5 million, up 119.6% year over year, and a GAAP net income of $5.2 million, or $0.10 per diluted share. On an adjusted basis, EBITDA stood at $24.4 million, or $0.48 per diluted share, reversing last year’s losses. Importantly, gross margin expanded to 73.6% from 65.8% a year ago, underscoring favorable product mix and pricing dynamics.

Key numbers at a glance

  • Net sales: $93.5 million, up 119.6% YoY
  • Net sales excluding China: $46.1 million, up 6.0% YoY
  • Gross margin: 73.6% (vs. 65.8% a year ago)
  • Net income: $5.2 million, or $0.10 per diluted share (GAAP)
  • Adjusted EBITDA: $24.4 million, or $0.48 per diluted share
  • Prior-year comparison: Adjusted EBITDA loss of $26.3 million, or $(0.53) per diluted share
  • Earnings call: Today at 5:30 PM Eastern

Context and interpretation

The quarter’s earnings profile reflects a rare combination for a medical device company: a sharp top-line acceleration paired with margin expansion and profitability on a GAAP basis. The contrast to last year’s loss highlights a dramatic swing in profitability that investors will scrutinize against expectations and capital discipline.

Analysts will likely weigh the result against EPS consensus expectations and the earnings surprise framework. Since the press release does not publish explicit consensus figures, indications of whether the quarter surpassed or lagged Street estimates will hinge on forthcoming guidance and retailer/analyst commentary. In other words, the “earnings surprise” tag here will depend on what consensus was dialing in for EPS and whether the market was priced for a stronger or softer micro-moment.

Operational drivers and geographic exposure

Net sales excluding China grew modestly on a YoY basis, suggesting that growth is broadening beyond the Chinese market while still exposing the company to regional demand shifts. The robust gross margin implies favorable product mix, pricing power, or operating leverage as the revenue base expands. The improvement in profitability is notable because it accompanies a sizable top-line increase, a combination investors often reward when sustained.

Forward-looking considerations

With an earnings call and webcast scheduled for today, investors will listen for cadence on future revenue forecast trajectories, potential margin expansion, and any commentary on capital allocation. The balance between accelerating net sales and maintaining or improving gross margin will shape sentiment around the stock’s risk-reward profile.

For sector peers, the print may reinforce expectations that EVO ICL adoption can drive sustained top-line growth while margin discipline remains critical. The China exposure, while a positive long-term growth vector for the franchise, remains a factor to watch as regional demand, regulatory environments, and reimbursement dynamics evolve.

Product narrative and shareholder letter

The company’s message emphasizes leadership in the phakic IOL space and the EVO line-up, signaling confidence in the growth trajectory of this niche but increasingly competitive field. The shareholder letter portion frames the quarter within a longer-term narrative of market expansion and technical leadership, a theme that could influence investor perceptions of durability beyond the current quarter.

Market implications and takeaways

For STAA, the quarter provides material fodder for bulls who credit the EVO portfolio with durable demand and for skeptics who want to see sustained margin expansion and EPS consensus alignment over multiple quarters. The numbers suggest the company is well-positioned to translate higher sales into profitability, provided pricing, mix, and operating efficiencies hold. For peers, the focus will remain on whether this quarterly performance signals a replicable playbook in ophthalmic implantable lenses or a temporary margin squeeze improved by one-off factors.

Bottom line

STAAR Surgical’s Q1 2026 results articulate a compelling narrative: surging revenue, improving gross margins, and a path back to profitability that could become a template for the sector if the momentum persists. The next few quarters will test whether the EPS, EBITDA trajectory, and revenue mix can sustain the lift and whether the market’s EPS expectations and revenue forecast revisions converge with reality. As with many specialized medical device stories, the near-term drama may be less about the headline number and more about the rhythm of growth and the durability of margins as the EVO family scales.

Reported by a correspondent who treats earnings disclosures like a puzzle with a chess clock. For investors following STAA, EPS readings, earnings surprise potential, EPS consensus alignment, and revenue forecast dynamics will stay at the center of the conversation as the year unfolds.